<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Neuraxis, Inc. — News on 6ix</title>
<link>https://6ix.com/company/neuraxis-inc</link>
<description>Latest news and press releases for Neuraxis, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/neuraxis-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d771e551cc36e47533e19b.webp</url>
<title>Neuraxis, Inc.</title>
<link>https://6ix.com/company/neuraxis-inc</link>
</image>
<item>
<title>NeurAxis Expands Payer Coverage with Four New Medical Policies</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-expands-payer-coverage-with-four-new-medical-policies</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-expands-payer-coverage-with-four-new-medical-policies</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced four additional health insurers with medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 1.25 million covered lives. These medical policies expand incremental access to IB-</description>
</item>
<item>
<title>NeurAxis, Inc. Announces Preferred Stock Dividend</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-inc-announces-preferred-stock-dividend</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-inc-announces-preferred-stock-dividend</guid>
<pubDate>Fri, 10 Apr 2026 11:00:00 GMT</pubDate>
<description>CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that on April 10, 2026, its Board of Directors declared a dividend on its Series B Preferred Stock. Holders of record of the Company’s Series B Preferred Stock (the “Series B Preferred Stock”) as of the close of business on April 2</description>
</item>
<item>
<title>NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-reports-strong-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-reports-strong-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 19 Mar 2026 11:05:00 GMT</pubDate>
<description>Conference call will be held today, Thursday, March 19 at 9:00 am ETCARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025. 4Q25 Financial Highlights Revenues increased 27% year over year to $968 thousand in 4Q</description>
</item>
<item>
<title>NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement Pathway</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-achieves-major-milestone-with-ama-category-i-cptr-code-now-in-effect-establishing-a-permanent-reimbursement-pathway</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-achieves-major-milestone-with-ama-category-i-cptr-code-now-in-effect-establishing-a-permanent-reimbursement-pathway</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization.The assignment of a Category I CPT® code demonstrates a strong message to payers, both commercial and government, that there is now a path to consistent reporting and reimbursement for providers in the medical community. CARMEL, Ind., Jan. 08, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commerciali</description>
</item>
<item>
<title>NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-achieves-medical-coverage-policy-milestone-expanding-access-to-approximately-45-million-additional-covered-lives</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-achieves-medical-coverage-policy-milestone-expanding-access-to-approximately-45-million-additional-covered-lives</guid>
<pubDate>Fri, 19 Dec 2025 13:00:00 GMT</pubDate>
<description>Total national coverage footprint for PENFS increases to roughly 100 million covered livesCARMEL, Ind., Dec. 19, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”). The</description>
</item>
<item>
<title>NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-secures-veterans-affairs-federal-supply-schedule-contract-broadening-access-to-more-patients-with-functional-abdominal-pain</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-secures-veterans-affairs-federal-supply-schedule-contract-broadening-access-to-more-patients-with-functional-abdominal-pain</guid>
<pubDate>Mon, 01 Dec 2025 12:00:00 GMT</pubDate>
<description>CARMEL, Ind., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that it has been awarded a Veterans Affairs (VA) Federal Supply Schedule (FSS) contract, effective December 1, 2025. The first product listed on the FSS is the IB-Stim®, a drug-free treatment for functional abdominal pain in patients</description>
</item>
<item>
<title>NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-announces-new-medical-policy-coverage-in-michigan-adding-566000-covered-lives</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>CARMEL, Ind., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 566,000 total covered lives, in Michigan. With this addition, approximately 82% of commercially insured pediatric ben</description>
</item>
<item>
<title>NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-reports-strong-third-quarter-2025-financial-results-driven-by-a-22percent-growth-in-revenues</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-reports-strong-third-quarter-2025-financial-results-driven-by-a-22percent-growth-in-revenues</guid>
<pubDate>Tue, 11 Nov 2025 12:00:00 GMT</pubDate>
<description>Conference call will be held today, Tuesday, November 11 at 9:00 am ETCARMEL, Ind., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the third quarter period ended September 30, 2025. 3Q25 Financial highlights Revenues increased 22% year over year to $811 thousand in 3Q25 compared t</description>
</item>
<item>
<title>NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-awarded-first-ever-fda-clearance-for-the-treatment-of-pain-in-functional-dyspepsia-fd-with-associated-nausea-symptoms-in-the-adult-patient-population</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-awarded-first-ever-fda-clearance-for-the-treatment-of-pain-in-functional-dyspepsia-fd-with-associated-nausea-symptoms-in-the-adult-patient-population</guid>
<pubDate>Fri, 24 Oct 2025 12:00:00 GMT</pubDate>
<description>Achieves significant expansion of NeurAxis’ total addressable marketClearance now includes patients aged “8 years and older”Expanded age indication will utilize the upcoming January 1st, 2026, Category I CPT code to report PENFS procedures CARMEL, Ind., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, t</description>
</item>
<item>
<title>NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-reports-strong-second-quarter-2025-financial-results-driven-by-a-46percent-growth-in-revenues</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-reports-strong-second-quarter-2025-financial-results-driven-by-a-46percent-growth-in-revenues</guid>
<pubDate>Tue, 12 Aug 2025 11:00:00 GMT</pubDate>
<description>Conference call will be held today, Tuesday, August 12 at 9:00 am ETCARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter 2025 for the period ended June 30, 2025. 2Q25 Financial highlights Revenues increased 46% year over year to $894 thousand in 2Q25 com</description>
</item>
<item>
<title>NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-announces-new-medical-policy-coverage-with-two-health-insurers-adding-700000-covered-lives</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-announces-new-medical-policy-coverage-with-two-health-insurers-adding-700000-covered-lives</guid>
<pubDate>Tue, 17 Jun 2025 12:00:00 GMT</pubDate>
<description>CARMEL, Ind., June 17, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), covering two health insurers, with approximately 700,000 total members in Connecticut and Massachusetts. This medical policy will bring our</description>
</item>
<item>
<title>NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-achieves-critical-milestone-secures-key-academic-society-guidelines-recommendation-for-treatment-of-functional-abdominal-pain-fap-in-ibs</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-achieves-critical-milestone-secures-key-academic-society-guidelines-recommendation-for-treatment-of-functional-abdominal-pain-fap-in-ibs</guid>
<pubDate>Tue, 10 Jun 2025 12:00:00 GMT</pubDate>
<description>Practice guidelines published in the Journal of Pediatric Gastroenterology & Nutrition (JPGN) name Percutaneous Electrical Nerve Field Stimulation (PENFS) as a recommended treatment option for FAP in IBSNeurAxis’s PENFS technology is the only FDA-cleared or approved treatment that is recommended in the guidelines for pediatrics, enabling momentum for large-scale insurance coverage for IB-Stim® CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE Ame</description>
</item>
<item>
<title>NeurAxis Announces Closing of $5.0 Million Registered Direct Offering</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-announces-closing-of-dollar50-million-registered-direct-offering</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-announces-closing-of-dollar50-million-registered-direct-offering</guid>
<pubDate>Thu, 22 May 2025 17:03:00 GMT</pubDate>
<description>Strengthens Balance Sheet and Provides Growth CapitalCARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the closing of its previously announced registered direct offering of 1,538,461 shares of its common stock at a purchase price of $3.25 per share. The gross proceeds from th</description>
</item>
<item>
<title>NeurAxis Announces $5.0 Million Registered Direct Offering</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-announces-dollar50-million-registered-direct-offering</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-announces-dollar50-million-registered-direct-offering</guid>
<pubDate>Wed, 21 May 2025 11:00:00 GMT</pubDate>
<description>CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,538,461 shares of its common stock at a purchase price of $3.25 per share in a registered direct offering priced at the market under</description>
</item>
<item>
<title>NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-awarded-first-ever-fda-clearance-for-the-treatment-of-pediatric-fapfunctional-dyspepsia-fd-and-associated-nausea-symptoms</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-awarded-first-ever-fda-clearance-for-the-treatment-of-pediatric-fapfunctional-dyspepsia-fd-and-associated-nausea-symptoms</guid>
<pubDate>Tue, 20 May 2025 12:00:00 GMT</pubDate>
<description>• Significantly expands IB-Stim’s total addressable market • Clearance covers patients aged 8–21 • Seamless go-to-market strategy with existing reimbursement and provider infrastructure CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has received FDA 510(k) clearanc</description>
</item>
<item>
<title>NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues</title>
<link>https://6ix.com/company/neuraxis-inc/news/neuraxis-reports-strong-first-quarter-2025-financial-results-driven-by-a-39percent-growth-in-revenues</link>
<guid isPermaLink="true">https://6ix.com/company/neuraxis-inc/news/neuraxis-reports-strong-first-quarter-2025-financial-results-driven-by-a-39percent-growth-in-revenues</guid>
<pubDate>Mon, 12 May 2025 12:15:00 GMT</pubDate>
<description>Conference call will be held today, Monday, May 12 at 9:00 am ETCARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025. 1Q25 Financial highlights Revenues increased 39% year over year to $896 thousand in 1Q25 compared</description>
</item>
</channel>
</rss>